Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3694)
All Articles published online
|
Sep 7, 2009 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | He ZL, Zheng H, Lin H, Miao XY, Zhong DW. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009; 15(33): 4177-4182 [PMID: 19725153 DOI: 10.3748/wjg.15.4177] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i33/4177.htm |
| Number | Citing Articles |
| 1 |
Zhao-Xia Wang, Dong Xue, Zhi-Li Liu, Bin-Bin Lu, Hai-Bo Bian, Xuan Pan, Yong-Mei Yin. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. The International Journal of Biochemistry & Cell Biology 2012; 44(1): 200 doi: 10.1016/j.biocel.2011.10.017
|
| 2 |
Shilpi Arora, Irma M Gonzales, R Tanner Hagelstrom, Christian Beaudry, Ashish Choudhary, Chao Sima, Raoul Tibes, Spyro Mousses, David O Azorsa. RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma. Molecular Cancer 2010; 9(1) doi: 10.1186/1476-4598-9-218
|
| 3 |
Mao-Wei Cheng, Bing-Chan Wang, Zhi-Qiang Weng, Xiao-Wei Zhu. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma. Acta Histochemica 2012; 114(5): 503 doi: 10.1016/j.acthis.2011.09.004
|
| 4 |
Ion Cristóbal, Federico Rojo, Juan Madoz-Gúrpide, Jesús García-Foncillas. Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. Molecular and Cellular Biology 2016; 36(12): 1734 doi: 10.1128/MCB.00130-16
|
| 5 |
Handy Riantana, Orawan Waenphimai, Panupong Mahalapbutr, Kun Karnchanapandh, Kulthida Vaeteewoottacharn, Sopit Wongkham, Kanlayanee Sawanyawisuth. BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines. Pathology - Research and Practice 2023; 248: 154678 doi: 10.1016/j.prp.2023.154678
|
| 6 |
Zhouxiang Liao, Qi Zhang, Lichao Yang, Hui Li, Wanling Mo, Zhenyu Song, Xuejing Huang, Sha Wen, Xiaojing Cheng, Min He. Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with PLK1 Variant rs27770A>G. Cancers 2023; 16(1): 129 doi: 10.3390/cancers16010129
|
| 7 |
Zhixian Liu, Qingrong Sun, Xiaosheng Wang. PLK1, A Potential Target for Cancer Therapy. Translational Oncology 2017; 10(1): 22 doi: 10.1016/j.tranon.2016.10.003
|
| 8 |
Ourania M. Andrisani, Leo Studach, Philippe Merle. Gene signatures in hepatocellular carcinoma (HCC). Seminars in Cancer Biology 2011; 21(1): 4 doi: 10.1016/j.semcancer.2010.09.002
|
| 9 |
Zili He, Wen Deng, Bo Jiang, Sulai Liu, Mingchun Tang, Yi Liu, Jian Zhang. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC. Gene 2018; 673: 46 doi: 10.1016/j.gene.2018.06.047
|
| 10 |
Ping Zhan, Guang‐min Xi, Bin Zhang, Ying Wu, Hong‐bing Liu, Ya‐fang Liu, Wu‐jian Xu, Qingqing Zhu, Feng Cai, Ze‐jun Zhou, Ying‐ying Miu, Xiao‐xia Wang, Jia‐jia Jin, Qian Li, Tang‐feng Lv, Yong Song. NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma. Journal of Cellular and Molecular Medicine 2017; 21(4): 665 doi: 10.1111/jcmm.13010
|
| 11 |
HAN ZHAO, JING GUO, QINGJIA CHI, MENG FANG. Molecular mechanisms of Tanshinone IIA in Hepatocellular carcinoma therapy via WGCNA-based network pharmacology analysis. BIOCELL 2022; 46(5): 1245 doi: 10.32604/biocell.2022.018117
|
| 12 |
Lily Weiß, Thomas Efferth. Polo-like kinase 1 as target for cancer therapy. Experimental Hematology & Oncology 2012; 1(1) doi: 10.1186/2162-3619-1-38
|
| 13 |
Ahmad Jalili, Anna Moser, Mikhail Pashenkov, Christine Wagner, Gaurav Pathria, Viola Borgdorff, Melanie Gschaider, Georg Stingl, Sridhar Ramaswamy, Stephan N. Wagner. Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology 2011; 131(9): 1886 doi: 10.1038/jid.2011.136
|
| 14 |
Yuchong Peng, Youhong Liu, Yingxue Gao, Bowen Yuan, Xuli Qi, Yuxin Fu, Qianling Zhu, Tuoyu Cao, Songwei Zhang, Linglong Yin, Xiong Li. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1457-8
|
| 15 |
Ayat G Lashen, Michael S Toss, Louisa Wootton, Andrew R. Green, Nigel P Mongan, Srinivasan Madhusudan, Emad Rakha. Characteristics and prognostic significance of polo‐like kinase‐1 (PLK1) expression in breast cancer. Histopathology 2023; 83(3): 414 doi: 10.1111/his.14960
|
| 16 |
Ding-pei Han, Qian-lin Zhu, Jiang-tao Cui, Pu-xiongzhi Wang, Shun Qu, Qi-feng Cao, Ya-ping Zong, Bo Feng, Min-hua Zheng, Ai-guo Lu. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Medical Science Monitor 2012; 18(6): BR237 doi: 10.12659/MSM.882900
|
| 17 |
Lin Luo, Xiao-Yang Zhang, Ying-Wei Zhen, Gao-Chao Guo, Da-Zhao Peng, Cheng Wei, Dong-Ling Pei, Bin Yu, Yu-Chen Ji, Xian-Zhi Liu, Lei Han, Zhen-Yu Zhang. Polo-like kinase 1 is related with malignant characteristics and inhibits macrophages infiltration in glioma. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1058036
|
| 18 |
So-Young Park, Daekwan Seo, Eun-Hye Jeon, Jee Park, Byeong-Churl Jang, Jee Kim, Seung-Soon Im, Jae-Ho Lee, Shin Kim, Chi Cho, Yun-Han Lee. RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling. International Journal of Oncology 2023; 63(2) doi: 10.3892/ijo.2023.5541
|
| 19 |
Aadil Javed, Gianluca Malagraba, Mahdieh Yarmohammadi, Catalina M. Perelló-Reus, Carles Barceló, Teresa Rubio-Tomás. Therapeutic Potential of Mitotic Kinases’ Inhibitors in Cancers of the Gastrointestinal System. Future Pharmacology 2022; 2(3): 214 doi: 10.3390/futurepharmacol2030015
|
| 20 |
Jörg Haupenthal, Verena Bihrer, Huedayi Korkusuz, Otto Kollmar, Christian Schmithals, Susanne Kriener, Knut Engels, Thomas Pleli, Alexander Benz, Marta Canamero, Thomas Longerich, Bernd Kronenberger, Swantje Richter, Oliver Waidmann, Thomas J. Vogl, Stefan Zeuzem, Albrecht Piiper. Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels. Neoplasia 2012; 14(5): 410 doi: 10.1596/neo.111366
|
| 21 |
Shufeng Wang, Xinzheng Wang, Xin Yang, Feng Liu, Jin Li, Weihua Li, Zhaofang Bai, Hongbo Wang, Jie Mao, Tingting Li, Kun He, Hongxia Wang. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. PROTEOMICS 2022; 22(4) doi: 10.1002/pmic.202100141
|
| 22 |
Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand, Anja Katrin Bosserhoff. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option. Oncotarget 2018; 9(3): 3605 doi: 10.18632/oncotarget.23188
|
| 23 |
Joshua A. McCarroll, Tanya Dwarte, Huricha Baigude, Jason Dang, Lu Yang, Rafael B. Erlich, Kathleen Kimpton, Joann Teo, Sharon M. Sagnella, Mia C. Akerfeldt, Jie Liu, Phoebe A. Phillips, Tariq M. Rana, Maria Kavallaris. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer. Oncotarget 2015; 6(14): 12020 doi: 10.18632/oncotarget.2664
|
| 24 |
Yiting Qiao, Yunxin Pei, Miao Luo, Muthukumar Rajasekaran, Kam M Hui, Jianxiang Chen. Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. Experimental Biology and Medicine 2021; 246(12): 1343 doi: 10.1177/15353702211008380
|
| 25 |
Andrew R. Conery, Ed Harlow. High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instability. Proceedings of the National Academy of Sciences 2010; 107(35): 15455 doi: 10.1073/pnas.1010627107
|
| 26 |
Hongli Gao, Zhuo Xi, Jingwei Dai, Jinqi Xue, Xin Guan, Liang Zhao, Zhiguang Chen, Fei Xing. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options. Molecular Cancer 2024; 23(1) doi: 10.1186/s12943-024-02005-y
|
| 27 |
Eman H. Yousef, Mohamed E El-Mesery, Maha R Habeeb, Laila A Eissa. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma. Tumor Biology 2020; 42(4): 101042832091447 doi: 10.1177/1010428320914475
|
| 28 |
Ariel Ka-Man Chow, Simon Wing-Lung Yau, Lui Ng. Novel molecular targets in hepatocellular carcinoma. World Journal of Clinical Oncology 2020; 11(8): 589-605 doi: 10.5306/wjco.v11.i8.589
|
| 29 |
Dongxiao Ding,, Dianqian Wang,, Yunsheng Qin. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma. Medicine 2023; 102(46): e36190 doi: 10.1097/MD.0000000000036190
|
| 30 |
Benchamart Moolmuang, Jittiporn Chaisaingmongkol, Pattama Singhirunnusorn, Mathuros Ruchirawat. PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells. Oncology Letters 2024; 28(1) doi: 10.3892/ol.2024.14449
|
| 31 |
Zewen Song, Zhaomei Yu, Limin Chen, Zhijiao Zhou, Qiong Zou, Yang Liu. MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1. Biomedicine & Pharmacotherapy 2019; 119: 109397 doi: 10.1016/j.biopha.2019.109397
|
| 32 |
Styliani Iliaki, Rudi Beyaert, Inna S. Afonina. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochemical Pharmacology 2021; 193: 114747 doi: 10.1016/j.bcp.2021.114747
|
| 33 |
Piotr Donizy, Agnieszka Halon, Pawel Surowiak, Maciej Kaczorowski, Cyprian Kozyra, Rafal Matkowski. Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up. Oncology Letters 2016; 12(3): 1667 doi: 10.3892/ol.2016.4890
|
| 34 |
James Ahodantin, Myriam Bou-Nader, Corinne Cordier, Jérôme Mégret, Patrick Soussan, Chantal Desdouets, Dina Kremsdorf. Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation. Oncogene 2019; 38(14): 2645 doi: 10.1038/s41388-018-0607-3
|
| 35 |
Liming Zhang, Shaoqiang Wang, Lina Wang. Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12975-3
|
| 36 |
Yuehong Wang, Linying Wu, Yinan Yao, Guohua Lu, Liming Xu, Jianying Zhou. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Letters 2018; 436: 1 doi: 10.1016/j.canlet.2018.08.007
|
| 37 |
Dingyue Zhang, Lixia Dong, Wenyong Yang, Kui Wang, Mibel Aguilar. Identification of NQO1 as a target of herbal drug agrimol B in hepatocellular carcinoma. Australian Journal of Chemistry 2023; 76(8): 465 doi: 10.1071/CH22255
|
| 38 |
Li Xu, Yuanrun Zhu, Jinjin Shao, Min Chen, Hao Yan, Guanqun Li, Yi Zhu, Zhifei Xu, Bo Yang, Peihua Luo, Qiaojun He. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. British Journal of Cancer 2017; 116(8): 1027 doi: 10.1038/bjc.2017.55
|
| 39 |
Wei Sun, Qi Su, Xiankui Cao, Bin Shang, Aishan Chen, Hongzhuan Yin, Baolin Liu. High Expression of Polo-Like Kinase 1 Is Associated with Early Development of Hepatocellular Carcinoma. International Journal of Genomics 2014; 2014: 1 doi: 10.1155/2014/312130
|
| 40 |
Qiying Yi, Yang Liu, Min Cao, Jianing Liu, Qin Xiang, Guo Tan, Huatang Zhang, Guoqi Lai, Yajun Xie. Transcriptional analysis and differentially expressed gene screening of spontaneous liver tumors in CBA/CaJ mice. Gene 2020; 725: 144159 doi: 10.1016/j.gene.2019.144159
|
| 41 |
Ping Chen, Xia Zhao, Liang Ma. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Molecular and Cellular Biochemistry 2013; 383(1-2): 49 doi: 10.1007/s11010-013-1753-0
|
| 42 |
Hicham Bouhlal, Hakim Ouled-Haddou, Véronique Debuysscher, Amrathlal Rabbind Singh, Christèle Ossart, Aline Reignier, Hakim Hocini, Gregory Fouquet, Mohammed Al Baghami, Mélanie Simoes Eugenio, Eric Nguyen-Khac, Jean-Marc Regimbeau, Ingrid Marcq. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget 2016; 7(9): 9832 doi: 10.18632/oncotarget.6954
|
| 43 |
J.C. Oliveira, J.A. Pezuk, M.S. Brassesco, A.G. Morales, R.G.P. Queiroz, C.A. Scrideli, L.G. Tone. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer 2014; 61(7): 1227 doi: 10.1002/pbc.24978
|
| 44 |
XING-GUANG ZHANG, XIAO-FENG LU, XIU-MING JIAO, BIN CHEN, JIN-XIAO WU. PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Experimental and Therapeutic Medicine 2012; 4(6): 1005 doi: 10.3892/etm.2012.729
|
| 45 |
Zhou Deng, Guyue Chen, Shuang Liu, Yunzhan Li, Jiaji Zhong, Baoding Zhang, Li Li, Huiying Huang, Zheng Wang, Qingyan Xu, Xianming Deng. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma. European Journal of Medicinal Chemistry 2020; 206: 112697 doi: 10.1016/j.ejmech.2020.112697
|
| 46 |
Claudia Münch, Diana Dragoi, Anna-Verena Frey, Katja Thurig, Michael Lübbert, Ralph Wäsch, Lioudmila Bogatyreva, Dieter Hauschke, Silke Lassmann, Martin Werner, Annette M. May. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leukemia Research 2015; 39(4): 462 doi: 10.1016/j.leukres.2015.01.007
|
| 47 |
Abdul K. Siraj, Pratheesh Kumar Poyil, Divya Padmaja, Sandeep Kumar Parvathareddy, Khadija Alobaisi, Saravanan Thangavel, Roxanne Diaz, Rafia Begum, Osama Almalik, Fouad Al-Dayel, Khawla S. Al-Kuraya. PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer. Frontiers in Oncology 2024; 13 doi: 10.3389/fonc.2023.1286585
|
| 48 |
Nitin Sharma, Rajni Vaid, Kamal Dev, Anuradha Sourirajan. Encyclopedia of Signaling Molecules. 2017; : 1 doi: 10.1007/978-1-4614-6438-9_101760-1
|
| 49 |
Hefei Li, Haibo Wang, Zhenqing Sun, Qiang Guo, Hongyun Shi, Youchao Jia. The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. Bioscience Reports 2017; 37(4) doi: 10.1042/BSR20170852
|
| 50 |
N. Stutz, M. Nihal, G.S. Wood. Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma. British Journal of Dermatology 2011; 164(4): 814 doi: 10.1111/j.1365-2133.2010.10128.x
|
| 51 |
Zihan Ran, Wenjie Chen, Jun Shang, Xuemei Li, Zhiyan Nie, Jingcheng Yang, Na Li. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis. Gene 2019; 721: 144097 doi: 10.1016/j.gene.2019.144097
|
| 52 |
Jung‐Sun Park, Hyun‐Jung Sohn, Gyeong‐Sin Park, Yeun‐Jun Chung, Tai‐Gyu Kim. Induction of antitumor immunity using dendritic cells electroporated with Polo‐like kinase 1 (Plk1) mRNA in murine tumor models. Cancer Science 2011; 102(8): 1448 doi: 10.1111/j.1349-7006.2011.01974.x
|
| 53 |
Nitin Sharma, Rajni Vaid, Kamal Dev, Anuradha Sourirajan. Encyclopedia of Signaling Molecules. 2018; : 4100 doi: 10.1007/978-3-319-67199-4_101760
|
| 54 |
Weiqiang Fan, Huan Ma, Bin Jin. Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma. Oncology Letters 2022; 23(5) doi: 10.3892/ol.2022.13266
|
| 55 |
Pauline Hascoet, Franck Chesnel, Cathy Le Goff, Xavier Le Goff, Yannick Arlot-Bonnemains. Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis. Frontiers in Oncology 2015; 5 doi: 10.3389/fonc.2015.00241
|
| 56 |
Otília Menyhárt, Ádám Nagy, Balázs Győrffy. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. Royal Society Open Science 2018; 5(12): 181006 doi: 10.1098/rsos.181006
|
| 57 |
Yingai Zhang, Shunlan Wang, Jingchuan Xiao, Hailong Zhou. Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma. Bioscience Reports 2019; 39(2) doi: 10.1042/BSR20181845
|
| 58 |
Neval Akdeli, Kathrin Riemann, Jana Westphal, Jochen Hess, Winfried Siffert, Hagen S Bachmann. A 3′UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1. Molecular Cancer 2014; 13(1) doi: 10.1186/1476-4598-13-87
|